Cargando…
Galectin-8 binds to the Farnesylated C-terminus of K-Ras4B and Modifies Ras/ERK Signaling and Migration in Pancreatic and Lung Carcinoma Cells
K-Ras is the most prominent driver of oncogenesis and no effective K-Ras inhibitors have been established despite decades of intensive research. Identifying new K-Ras-binding proteins and their interaction domains offers the opportunity for defining new approaches in tackling oncogenic K-Ras. We hav...
Autores principales: | Meinohl, Christopher, Barnard, Sarah J., Fritz-Wolf, Karin, Unger, Monika, Porr, Andreea, Heipel, Marisa, Wirth, Stefanie, Madlung, Johannes, Nordheim, Alfred, Menke, Andre, Becker, Katja, Giehl, Klaudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017085/ https://www.ncbi.nlm.nih.gov/pubmed/31861875 http://dx.doi.org/10.3390/cancers12010030 |
Ejemplares similares
-
Reversal of the Ras-Induced Transformed Phenotype by Hr12, a Novel Ras Farnesylation Inhibitor, Is Mediated by the Mek/ERK Pathway
por: Reuveni, Hadas, et al.
Publicado: (2000) -
VPS35 binds farnesylated N-Ras in the cytosol to regulate N-Ras trafficking
por: Zhou, Mo, et al.
Publicado: (2016) -
RAS Dimers: The Novice Couple at the RAS-ERK Pathway Ball
por: Herrero, Ana, et al.
Publicado: (2021) -
Manumycin and gliotoxin derivative KT7595 block Ras farnesylation and cell growth but do not disturb lamin farnesylation and localization in human tumour cells.
por: Nagase, T., et al.
Publicado: (1997) -
The C-Terminus of H-Ras as a Target for the Covalent Binding of Reactive Compounds Modulating Ras-Dependent Pathways
por: Oeste, Clara L., et al.
Publicado: (2011)